J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment
Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...
Cancer
GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension
The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...
GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment
UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...
Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China
China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...
Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors
On December 13, 2024, Innovent Biologics, Inc. (HKG: 1801) registered a Phase I clinical trial...
Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I...
Pfizer’s Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial
US pharmaceutical major Pfizer Inc. (NYSE: PFE) and Alliance Foundation Trials, LLC (AFT) have announced...
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...
Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...
Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has announced receiving marketing approval from...
Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer
Immunofoco, a leading developer in tumor immunotherapy based in Suzhou, has announced that it has...
Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...
Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...
CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...
AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that the US Food and Drug...
AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
UK-based pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN) has announced positive results from the PACIFIC-5 III...
Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...